<DOC>
	<DOCNO>NCT00003606</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether combination chemotherapy without epirubicin cyclophosphamide effective treating patient extensive stage small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without epirubicin cyclophosphamide treat patient extensive stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival survival without recurrence patient extensive stage small cell lung cancer receive cisplatin etoposide without epirubicin cyclophosphamide . II . Compare relative dose intensity cisplatin etoposide two group patient . III . Compare complete objective response rate quality life patient . IV . Compare toxic effect 2 regimen patient . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive etoposide IV day 1 3 cisplatin IV day 2 . Arm II : Patients receive etoposide cisplatin arm I , plus epirubicin IV day 1 cyclophosphamide IV day 1 3 . Treatment repeat arm every 28 day 6 course . Patients achieve partial complete response receive cerebral and/or thoracic radiotherapy . Patients residual tumor may receive oral etoposide 3 every 4 week . Patients follow every 3 month . PROJECTED ACCRUAL : A total 216 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven extensive stage small cell lung cancer Extends beyond hemithorax supraclavicular lymph node Pleural effusion allow Bidimensionally measurable disease Bone marrow metastasis allow No symptomatic CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 75 Performance status : 02 Life expectancy : Not specify Hematopoietic : Neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal Renal : Creatinine le 1.24 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No cardiac insufficiency No uncontrolled cardiac disease LVEF great 50 % OR ECHO great 30 % Other : Not pregnant Fertile patient must use effective contraception No psychoses No active infection No loss weight great 10 % last 3 month No malignancy except nonmelanomatous skin cancer stage I cervical cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent immunotherapy Chemotherapy : No prior concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior concurrent radiotherapy Surgery : No prior concurrent surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>